

ABSTRACT

The present invention relates to a lipid-based drug delivery system for administration of a lysolipid derivative present in prodrug form, said prodrug furthermore being a substrate for
5 extracellular phospholipase A₂ to the extent that an organic radical can be hydrolytically
cleaved off, whereas the aliphatic group of the lysolipid derivative remains substantially
unaffected, said system having included therein lipopolymers or glycolipids so as to
present hydrophilic chains on the surface of the system. Particularly interesting lipid
derivatives are ether lipids and ether lipids in which drug substance is covalently attached
10 in the *sn*-2-position. Pharmaceutical compositions comprising the drug delivery system
can be used in the targeted treatment of various disorders, e.g. cancer, infectious, and
inflammatory conditions, etc., i.e. disorders and diseases associated with or resulting from
increased levels of extracellular PLA₂ activity in the diseased tissue.